ETNB 89bio, Inc. Insider Trading

RA Capital Management (director) purchases 5,714,285 shares of ETNB at $8.75; $50.0M total position builds to 19.55M shares (+41.3%)

RA Capital Management, L.P. deployed $50.0M to acquire 5,714,285 shares of 89bio at $8.75, increasing its shareholding by 41.3% to 19.55M shares total. The transaction occurred at a price 5.8% below current market levels ($9.29), and notably below the 52-week high of $13.77. The company remains unprofitable with a full-year net income of $-149.1M, placing this purchase within a loss-making operating environment. The insider's cross-ticker track record across 18 prior buys shows an average 30-day return of +224.2% and 90-day return of +220.7%, though this performance is not ticket-specific and ETNB-tailored outcomes are not measured in the public filing.

Director McWherter bought 15,000 shares at $6.55-$6.71 (blended $6.66) on Jan 21-22; holds 25,000 post-transaction.

Director Charles McWherter made 2 separate purchases totaling 15,000 shares for $99,850.00 over January 21-22, increasing his stake by 150.0% from 10,000 to 25,000 shares. The purchases at $6.55–$6.71 occurred as the stock trades 49.8% below its 52-week high of $13.77, and the company reported a negative net income of $-149,073,000.00 for its most recent full fiscal year. His single prior open-market buy at ETNB (December 5, 2024) showed a 30-day return of -0.5%, and his cross-ticker track record across all holdings shows 1 prior buy with an average 30-day return of -0.5%, establishing a pattern without measurable success in recent timing. The purchase into an unprofitable, declining-price environment warrants scrutiny of whether this reflects access to non-public information or represents a discretionary conviction call in a challenging fundamental backdrop.

CEO Rohan buys 5,000 ETNB shares at $7.89; stock down 41.9% from 52-week high, company posts -$149.1M net loss.

CEO Palekar Rohan purchased 5,000 shares at $7.89 on 2024-12-06, increasing his holdings to 471.2K shares. The purchase occurs as 89bio trades significantly below its 52-week high at $13.77, currently at $8.00, and follows a steep 23.4% decline over the prior 30 days. This marks Rohan's second open-market buy transaction in his track record, preceded by two sales with a 50.00% 90-day well-timed rate at other tickers. At ETNB specifically, Rohan has conducted three prior trades: a buy on 2024-11-22 (outcome not yet measurable), a sell on 2024-04-01 (90d return -26.6%), and a sell on 2024-12-29 (90d return +3.9%), with only 1 of 2 prior trades well-timed at the 90-day mark. The company reported a full-year net loss of -$149.1M with a market cap of $849.0M, indicating significant operational challenges. The close timing of the November and December buys warrants investor attention to whether deterioration has stabilized or if additional insider activity follows.

ETNB Director McWherter purchases 10,000 shares at $8.00; stock down 41.7% from 52-week high amid $-149.1M annual loss.

Charles McWherter, a director of 89bio, initiated a first position in the company by purchasing 10,000 shares at $8.00 on 2024-12-05, investing $80,000.00 total. The transaction occurs against a backdrop of significant operational challenges: the company posted a net income of $-149,073,000.00 over its most recent full fiscal year and the stock has declined 41.7% from its 52-week high of $13.77, trading near the lower end of its annual range at $8.03. The purchase follows a steep 30-day decline of 23.2%, suggesting the director acquired shares after a recent selloff. With the company unprofitable and the stock under pressure, this transaction reflects a substantial commitment by a board member at a depressed valuation point, though the company's loss-making status limits confidence in near-term inflection.

ETNB CEO Rohan bought 10,000 shares at $8.35 on 2024-11-22; stock down -34.9% from 52-week high amid unprofitability

ETNB CEO Rohan purchased 10,000 shares at $8.35 on 2024-11-22, increasing his holdings from 456,236 to 466,236 shares. The transaction follows a sharp drawdown: the stock trades -34.9% from its 52-week high of $13.77 and has declined -2.0% over the past 90 days despite a +13.8% bounce in the past month. The company posted a net income of $-149,073,000.00 for its most recent full fiscal year, indicating continued unprofitability. While the recent 30-day price recovery is notable, Rohan's own historical sales at this ticker show mixed timing: his two prior ETNB sales yielded 90-day returns of -26.6% and +3.9%, placing him 1 of 2 well-timed at the 90-day mark. The open-market purchase at a depressed price level merits observation for whether it represents conviction in a recovery from an unprofitable operating state.